Latigo Biotherapeutics Inc.
LTGO
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $1.4B
$23.04
▲ +2.49%
P/E
—
Mkt Cap
$1.4B
52-Wk Range
$17.22–$25.93
52-Week Range
$17.22 - $25.93
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 28.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
No forward estimates available
Value
Valuation data unavailable
Momentum
Hot
+28.0% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LTGO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
SEP 3, 2026
Reported EPS of -$0.65 vs -$0.62 consensus (-5.4% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-5.4%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Sep 1, 2026
vs Industry
How LTGO stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.